We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


The role of transplant in mantle cell lymphoma

Monday, May 22, 2017

Peter Martin, M.D., assistant professor of medicine, talks to OncLive about the role of transplant in the field of mantle cell lymphoma (MCL). Right now, for those patients who can tolerate intensive therapy who want a very long remission duration or long treatment-free interval, high-dose cytarabine followed by autologous transplant is likely the best way to achieve that, Martin explains.

There is clearly a group of patients who should undergo transplant, but there are also many patients who can have very good outcomes without transplant.

However, the difference between the 2 groups is that the latter will likely need to be administered more therapies during what would be a treatment-free interval. 

Dr. Martin also discussed the evolving field of mantle cell lymphoma treatment in an interview with CURE Magazine. Read the full article here.